BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

5093 related articles for article (PubMed ID: 19018742)

  • 1. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal osteodystrophy in dialysis patients: diagnosis and treatment.
    Fournier A; Oprisiu R; Hottelart C; Yverneau PH; Ghazali A; Atik A; Hedri H; Said S; Sechet A; Rasolombololona M; Abighanem O; Sarraj A; El Esper N; Moriniere P; Boudailliez B; Westeel PF; Achard JM; Pruna A
    Artif Organs; 1998 Jul; 22(7):530-57. PubMed ID: 9684690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interventions for metabolic bone disease in children with chronic kidney disease.
    Hahn D; Hodson EM; Craig JC
    Cochrane Database Syst Rev; 2015 Nov; 2015(11):CD008327. PubMed ID: 26561037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of alkaline calcium salts as phosphate binder in uremic patients.
    Fournier A; Morinière P; Ben Hamida F; el Esjer N; Shenovda M; Ghazali A; Bouzernidj M; Achard JM; Westeel PF
    Kidney Int Suppl; 1992 Oct; 38():S50-61. PubMed ID: 1405382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical utility of vitamin d testing: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(2):1-93. PubMed ID: 23074397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Vitamin D treatment and renal osteodystrophy: indications and modalities].
    Fournier A; Morinière P; Yverneau-Hardy P; Westeel PF; Mazouz H; el Esper N; Ghazali A; Boudailliez B
    Nephrologie; 1995; 16(2):165-90. PubMed ID: 7753302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term effects of intravenous 1 alpha (OH)D3 combined with CaCO3 and low-calcium dialysis on secondary hyperparathyroidism and biochemical bone markers in patients on chronic hemodialysis.
    Brandi L; Daugaard H; Nielsen PK; Jensen LT; Egsmose C; Olgaard K
    Nephron; 1996; 74(1):89-103. PubMed ID: 8883025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Hyperparathyroidism secondary to renal insufficiency. Physiopathology, clinicoradiological aspects and treatment].
    Ben Hamida F; Ghazali A; Boudzernidj M; Amar M; Morinière P; Westeel P; Fournier A
    Ann Endocrinol (Paris); 1994; 55(5):147-58. PubMed ID: 7857079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High prevalence of secondary hyperparathyroidism in chronic kidney disease patients on dialysis in Argentina.
    Douthat WG; Castellano M; Berenguer L; Guzmán MA; de Arteaga J; Chiurchiu CR; Massari PU; Garay G; Capra R; de La Fuente JL
    Nefrologia; 2013; 33(5):657-66. PubMed ID: 24089157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphate binders, vitamin D and calcimimetics in the management of chronic kidney disease-mineral bone disorders (CKD-MBD) in children.
    Wesseling-Perry K; Salusky IB
    Pediatr Nephrol; 2013 Apr; 28(4):617-25. PubMed ID: 23381010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parathyroid hormone increases bone formation and improves mineral balance in vitamin D-deficient female rats.
    Toromanoff A; Ammann P; Mosekilde L; Thomsen JS; Riond JL
    Endocrinology; 1997 Jun; 138(6):2449-57. PubMed ID: 9165035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correction of vitamin D status by calcidiol: pharmacokinetic profile, safety, and biochemical effects on bone and mineral metabolism of daily and weekly dosage regimens.
    Minisola S; Cianferotti L; Biondi P; Cipriani C; Fossi C; Franceschelli F; Giusti F; Leoncini G; Pepe J; Bischoff-Ferrari HA; Brandi ML
    Osteoporos Int; 2017 Nov; 28(11):3239-3249. PubMed ID: 28815282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of oral phosphorus supplementation on mineral metabolism of renal transplant recipients.
    Caravaca F; Fernández MA; Ruiz-Calero R; Cubero J; Aparicio A; Jimenez F; García MC
    Nephrol Dial Transplant; 1998 Oct; 13(10):2605-11. PubMed ID: 9794568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of CAPD and hemodialysis on parathyroid function.
    Malberti F; Corradi B; Imbasciati E
    Adv Perit Dial; 1996; 12():239-44. PubMed ID: 8865912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The roles of calcium and 1,25-dihydroxyvitamin D3 in the regulation of vitamin D receptor expression by rat parathyroid glands.
    Brown AJ; Zhong M; Finch J; Ritter C; Slatopolsky E
    Endocrinology; 1995 Apr; 136(4):1419-25. PubMed ID: 7895652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progress in pharmacotherapy for the treatment of hyperphosphatemia in renal failure.
    Cernaro V; Longhitano E; Calabrese V; Casuscelli C; Di Carlo S; Spinella C; Gembillo G; Santoro D
    Expert Opin Pharmacother; 2023; 24(15):1737-1746. PubMed ID: 37527180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential changes of biochemical bone parameters after kidney transplantation.
    Reinhardt W; Bartelworth H; Jockenhövel F; Schmidt-Gayk H; Witzke O; Wagner K; Heemann UW; Reinwein D; Philipp T; Mann K
    Nephrol Dial Transplant; 1998 Feb; 13(2):436-42. PubMed ID: 9509459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone mineral density and biochemical markers of bone turnover in patients with predialysis chronic renal failure.
    Rix M; Andreassen H; Eskildsen P; Langdahl B; Olgaard K
    Kidney Int; 1999 Sep; 56(3):1084-93. PubMed ID: 10469378
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 255.